{"id":1913,"date":"2024-12-21T16:57:10","date_gmt":"2024-12-21T13:57:10","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=1913"},"modified":"2025-06-21T13:49:54","modified_gmt":"2025-06-21T10:49:54","slug":"uk-approves-givinostat-duvyzat-for-duchenne-muscular-dystrophy-treatment","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/tr\/uk-approves-givinostat-duvyzat-for-duchenne-muscular-dystrophy-treatment\/","title":{"rendered":"\u0130ngiltere, Duchenne Musk\u00fcler Distrofi Tedavisi i\u00e7in Givinostat&#039;\u0131 (Duvyzat) Onaylad\u0131"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Givinostat conditionally approved to treat patients with Duchenne muscular dystrophy (DMD).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In a significant development for patients with Duchenne muscular dystrophy (DMD), the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a conditional marketing authorisation for the medicine givinostat, also known as Duvyzat.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This approval, announced on 20 December 2024, marks a crucial step forward in the treatment of this debilitating genetic disorder.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Givinostat is a nonsteroidal drug indicated for the treatment of patients aged 6 years of age and older with all genetic variants of DMD. [Read more: <a href=\"https:\/\/dmdwarrior.com\/duvyzat-givinostat-nonsteroidal-drug\/\" target=\"_blank\" data-type=\"post\" data-id=\"1462\" rel=\"noreferrer noopener\">What is Duvyzat (Givinostat)?<\/a>]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Givinostat conditionally approved to treat patients with Duchenne muscular dystrophy (DMD). In a significant development for patients with Duchenne muscular dystrophy (DMD), the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a conditional marketing authorisation for the medicine givinostat, also known as Duvyzat. This approval, announced on 20 December 2024, marks a crucial step [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1916,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[45],"tags":[46,49,47,50,48],"class_list":["post-1913","post","type-post","status-publish","format-standard","has-post-thumbnail","category-approved-therapies-for-duchenne-muscular-dystrophy","tag-duvyzat","tag-england","tag-givinostat","tag-mhra","tag-uk"],"subtitle":"MHRA'n\u0131n ko\u015fullu onay\u0131, givinostat'\u0131n alt\u0131 ya\u015f ve \u00fczeri DMD hastalar\u0131nda kullan\u0131lmas\u0131na izin veriyor ve hastal\u0131\u011f\u0131n t\u00fcm genetik varyantlar\u0131na uygulanabilir. Bu karar, ABD G\u0131da ve \u0130la\u00e7 Dairesi'nin (FDA) bu y\u0131l\u0131n ba\u015flar\u0131nda givinostat'\u0131 onaylamas\u0131n\u0131n ard\u0131ndan geldi.","_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/1913","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/comments?post=1913"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/1913\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media\/1916"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media?parent=1913"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/categories?post=1913"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/tags?post=1913"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}